👀 Jessica R Newton-Northup

🔍 Search 📋 Browse 🏷 Tags ❀ Favourites ➕ Add 🧬 Extraction
1
Articles
articles

Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs.

Sandra M Axiak-Bechtel, Stacey B Leach, David G Scholten +5 more · 2021 · Pharmacology research & perspectives · Wiley · added 2026-04-24
The melanocortin-4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 adminis Show more
The melanocortin-4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high- (2.25 mg kg Show less
📄 PDF DOI: 10.1002/prp2.777
MC4R